Trials / Completed
CompletedNCT04250181
High Power vs Standard Power RF Ablation of Atrial Fibrillation in Conscious Patients
HPvSP-AF Trail: Is High RF Energy Ablation of Atrial Fibrillation Fast, Safe, Less Painful and Effective - a Propensity Score Matched Analysis of 30/25W, 40W and 50W RF Energy Settings
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Medical University of Lublin · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
High RF energy ablation of atrial fibrillation is fast, safe, less painful and effective procedure.
Detailed description
Atrial fibrillation (AF) ablation is the most commonly performed radiofrequency (RF) ablation and is usually associated with a long procedural time and sensation of pain in conscious patients. Prolonged radiation exposure during the procedure puts the patient and the operator at risk of malignancy and genetic abnormalities. Complications such as asymptomatic cerebral lesions, tamponade, perforation, and also arrhythmia recurrence were associated with longer ablation time. High-power, shorter-duration radiofrequency ablation (HPSDRFA) appears to be a novel concept for atrial fibrillation (AF) but there are scarce data in conscious patients. The lesion side index (LSI) value has been associated with durability of pulmonary vein isolation (PVI) lesions. We hypothesised that HPSDRFA applications based on the lesion side index (LSI; its has been associated with durability of pulmonary vein isolation (PVI) lesions) which were not inferior to standard approach regarding safety and effectiveness with shorten procedure time and being less painful for a patient.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | RF ablation of atrial fibrillation | Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation |
Timeline
- Start date
- 2019-11-15
- Primary completion
- 2020-01-20
- Completion
- 2020-02-08
- First posted
- 2020-01-31
- Last updated
- 2020-02-18
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT04250181. Inclusion in this directory is not an endorsement.